Navigation Links
MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics
Date:4/7/2008

ines. The company applies its proprietary inhalation technologies to enhance the therapeutic benefits and commercial attractiveness of proven drugs while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. MAP Pharmaceuticals has two drug candidates, Unit Dose Budesonide and MAP0004, in late stage development for the potential treatment of pediatric asthma and migraine respectively. MAP Pharmaceuticals' pipeline also includes a drug candidate in early clinical development for the treatment of asthma and chronic obstructive pulmonary disease.

Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com.

Forward-Looking Statements

In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to the further development of MAP0005 and the potential application of MAP Pharmaceuticals' technologies to additional product candidates. Actual results may differ materially from current expectations based on risks and uncertainties affecting the Company's business, including, without limitation, risks and uncertainties relating to the development and commercialization of product candidates incorporating MAP Pharmaceuticals' technologies. The reader is cautioned not to unduly rely on the forward- looking statements contained in this press release. MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Annual Report on Form 10K, filed with the SEC on March 20, 2008, available at http://edgar.sec.gov.


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Transdel Pharmaceuticals Advances Lead Topical Pain Drug into Phase 3 Program
2. VIA Pharmaceuticals Announces Updated DSMB Safety Results for VIA-2291 Ongoing Phase 2 Clinical Program
3. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
4. EnVivo Pharmaceuticals Announces Initiation of Clinical Safety and Biomarker Study of Alpha-7 Nicotinic Agonist, EVP-6124, in Patients with Schizophrenia
5. ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation
6. Monogram Biosciences Provides Progenics Pharmaceuticals with HIV Assays for Use in Clinical Trials
7. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
8. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
9. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
10. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
11. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)...  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced the ... common stock and warrants at a price of $10,000 ... to deducting underwriting discounts and commissions and offering expenses ... immediately separable and will be issued separately.  The shares ... The NASDAQ Stock Market under the ticker symbol "WGBS" ...
(Date:8/21/2014)... 2014   Memorial Hermann Health System and ... announced a new partnership to provide a new level of ... centers in the greater Houston area. ... the exclusive provider of professional breast radiology services for five ... City, The Woodlands , Northeast, Southwest and ...
(Date:8/21/2014)... Nektar Therapeutics (NASDAQ: NKTR ... results from its Phase 3 pivotal clinical trial ... factor VIII (rFVIII) treatment for hemophilia A based ... primary endpoint in reducing annualized bleed rates (ABR) ... arm. Top-line results from the prospective, ...
Breaking Medicine Technology:WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5
(Date:8/22/2014)... 22, 2014 For patients who need surgery for ... procedure is the least often used, reports a study ... , official journal of the Congress of Neurological ... Williams & Wilkins , a part of Wolters ... good pain relief at much lower cost than other ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Pirate ... expansion of products in providing new recipe cards, fun ... wear. , Hailing from Clearwater, Florida, Pirate Jonny, ... having 1 card with two to three recipes featuring ... recipes on the website. The recipe ...
(Date:8/22/2014)... Society for Medical Oncology (ESMO), the leading pan-European ... names of three outstanding individuals receiving the Society,s ... to Carsten Bokemeyer, Heikki Joensuu and Peter Boyle ... 26-30 September, Madrid, Spain. , Carsten Bokemeyer will ... accelerate the transition of cancer discovery into real ...
(Date:8/22/2014)... 22, 2014 A new study finds a wide ... may be related to key environmental exposuresin children with Crohn,s ... official journal of the Crohn,s & Colitis Foundation of ... Lippincott Williams & Wilkins , a part of Wolters ... evidence" of alterations of DNA in several regions of the ...
(Date:8/22/2014)... recall the dramatic images of nurses at New York ... hundred patients, carrying many including the youngest and most ... resulting from the storm surge generated by Hurricane Sandy. ... the New York University Colleges of Nursing (NYUCN) and ... Urban Health examines the impact on NYULMC nurses, ...
Breaking Medicine News(10 mins):Health News:More common procedures for painful facial tics carry high costs, reports study in Neurosurgery 2Health News:Pirate Jonny's Caribbean BBQ Rubs, Seasonings & Sauces Get New Look by Hoisting New Recipe Card Creations and New Clothing Apparel for its Logos 2Health News:ESMO honors outstanding oncology professionals 2Health News:ESMO honors outstanding oncology professionals 3Health News:Study shows epigenetic changes in children with Crohn's disease 2Health News:Study identifies challenges faced by NYU nurses after Hurricane Sandy 2Health News:Study identifies challenges faced by NYU nurses after Hurricane Sandy 3
... Amanda Gardner HealthDay Reporter , MONDAY, Oct. 11 ... higher risk for stroke even if they don,t have full-blown ... people who show signs of insulin resistance -- a reduction ... from the bloodstream -- may be helpful in preventing stroke, ...
... Health care in the last six months of life has ... among Medicare beneficiaries in the United States and older adults ... final six months of life in both countries, according to ... the February 14 print issue of Archives of Internal ...
... retinal conditions nearly doubled between 1997 and 2007, with ... performed, according to a report in the October issue ... JAMA/Archives journals. "Retinal disease is highly prevalent among ... diabetic retinopathy account for more than half the irreversible ...
... , MONDAY, Oct. 11 (HealthDay News) -- Pre-teens who spent ... TV or computer were at greater risk of having psychological ... kids also tended to be physically active, new research finds. ... November print issue of Pediatrics , found that the ...
... By Jenifer Goodwin HealthDay Reporter , ... have jaundice may be at higher risk of developing ... said far more research needs to be done before ... analyzed information from national registries that included all Danish ...
... disparities in the receipt of breast cancer care persist ... status. That is the conclusion of a study published ... of the American Cancer Society. The findings suggest that ... breast cancer care and to ensure that all affected ...
Cached Medicine News:Health News:Insulin Resistance Might Raise Risk of Stroke 2Health News:Insulin Resistance Might Raise Risk of Stroke 3Health News:End-of-life care patterns shift for patients with heart failure in both US and Canada 2Health News:End-of-life care patterns shift for patients with heart failure in both US and Canada 3Health News:End-of-life care patterns shift for patients with heart failure in both US and Canada 4Health News:End-of-life care patterns shift for patients with heart failure in both US and Canada 5Health News:Treatment of retinal conditions appears to have changed significantly in previous decade 2Health News:Could Excess Computer, TV Time Harm Kids Psychologically? 2Health News:Could Excess Computer, TV Time Harm Kids Psychologically? 3Health News:Danish Study Suggests Jaundice-Autism Link 2Health News:Danish Study Suggests Jaundice-Autism Link 3Health News:Insurance and socioeconomic status do not explain racial disparities in breast cancer care 2
... and fourth year medical students on ... easy access in a rapid-fire Q&A ... lab coat pocket, this reference is ... prior to surgical rounds as well ...
With its extensive content and custom-designed user interface, Schwartz Principles of Surgery, PDA Edition enables you quick access to the answers you need to make the right diagnosis or initiate a t...
This handy reference contains all of the essential information that surgical residents and medical students need to have at their fingertips for day-to-day patient care....
This book includes orthopedic, reproductive, renal, cardiovascular, GI, and respiratory problems; and other common conditions....
Medicine Products: